RE:RE:RE:RE:RE:Acquisition Accounting ..... Love it!
Good try Lattice but here is the problem with what you are saying. There is not one but many substitutes for Dibenzyline. Here is the complete list: https://www.fda.gov/downloads/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm183605.pdf The problem with substitutes (generics) is this. They have to be not only shown to be bioequivalent to the drug that they are replacing (and you can look up what it means for a drug to be bioequivalent) but there may also be differences in two products even when they are deemed to be bioequivalent. And this where the judgement of a health professional comes in. There are patients to watch out for. They may not react in the same way to a generic so just because a generic comes on the scene does not mean that the cash flow for the original is going to dry up. That is why in one of my previous posts I pointed out the patient approvals for a drug like Donnatal.